Stability of flucytosine 50 mg/mL in extemporaneous oral liquid formulations

VandenBussche, Heather L.; Johnson, Cary E.; Yun, Jin; Patel, S.

doi:10.1093/ajhp/59.19.1853

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[2][3][4][5][6][7] To our knowledge, there are no published reports of studies to evaluate whether meloxicam and carprofen remain stable after commercial liquid forms are diluted or commercial caplet forms are crushed and suspended. [2][3][4][5][6][7] To our knowledge, there are no published reports of studies to evaluate whether meloxicam and carprofen remain stable after commercial liquid forms are diluted or commercial caplet forms are crushed and suspended.…”

Section: Drug Distribution and Stability In Extemporaneous Preparatiomentioning

confidence: 99%

Drug distribution and stability in extemporaneous preparations of meloxicam and carprofen after dilution and suspension at two storage temperatures

Hawkins¹,

Karriker²,

Wiebe³

et al. 2006

javma

View full text Add to dashboard Cite

show abstract

Section: Drug Distribution and Stability In Extemporaneous Preparatiomentioning

confidence: 99%

Drug distribution and stability in extemporaneous preparations of meloxicam and carprofen after dilution and suspension at two storage temperatures

Hawkins¹,

Karriker²,

Wiebe³

et al. 2006

javma

View full text Add to dashboard Cite

show abstract

Stability of flucytosine 100 mg/mL suspension as an alternative to intravenous administration

Huang,

Corallo,

Chiang

et al. 2024

Pharmacy Practice and Res

View full text Add to dashboard Cite

BackgroundFlucytosine is an antifungal agent used in combination with other medicines for the treatment of fungal infections. It was available as intravenous (IV), oral tablet, and capsule formulations up until October 2021, when the IV product, Ancotil, was discontinued with no alternative brands available.AimThis study aimed to formulate a suitable formulation with appropriate stability data for medium to long‐term nasogastric (NG) administration use.MethodFlucytosine 500 mg tablets (Ancotil) were crushed and suspended in (1) Ora‐Plus (OP) + Ora‐Sweet (OS) and (2) Ora‐Blend (OB) to produce 100 mg/mL suspensions (n = 3 for each suspending base) that were stored at 2–8°C in amber glass bottles until assayed. Appearance, odour and pH, and the concentrations of flucytosine in the suspensions were determined by high‐performance liquid chromatography on days 1, 8, and 15. A subjective assessment of the ease of suspension for NG administration via a size 10fr nasogastric tube (NGT) was also tested. Ethics approval was not required for this research article as it was a stability study and did not contain human participants or human data.ResultsOne of the three OB suspension bottles demonstrated significant suspension clumping resulting in all OB suspensions being excluded from further analysis. There was no change in appearance, odour or pH with the OP + OS based flucytosine suspensions and they extruded easily through a size 10fr NGT with minimal force. The three OP + OS bottles of flucytosine suspension were stable (>98% at all timepoints assessed) for 15 days at 2–8°C when stored in amber glass bottles.ConclusionsThe OP + OS suspensions showed chemical stability for up to 15 days when stored under refrigerated conditions and protected from light, making this a suitable multidose enteral alternative to IV flucytosine.

show abstract

Successful Treatment of Candida auris Ventriculitis With Intravenous Liposomal Amphotericin B and Oral Flucytosine: A Case Report

Kang,

Hsu,

Bailey

2024

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Candida auris is a rapidly emerging fungal pathogen associated with high resistance rates, particularly in healthcare settings. It most commonly affects patients with severe underlying medical conditions and requiring complex medical care. Patients with invasive medical devices tend to be at increased risk for getting Candida auris and developing infection. This paper presents a case of Candida auris ventriculitis successfully treated with intravenous liposomal amphotericin B and oral flucytosine. A 41-year-old male with multiple comorbidities, including recent placement of a ventriculoperitoneal shunt, presented with suspected sepsis. Candida auris was isolated from cerebrospinal fluid cultures. Antifungal therapy along with removal of the shunt led to resolution of infection without complications. This case highlights the challenges posed by Candida auris infections and underscores the importance of appropriate treatment strategies.

show abstract

Stability of flucytosine 50 mg/mL in extemporaneous oral liquid formulations

Cited by 5 publications

References 0 publications

Drug distribution and stability in extemporaneous preparations of meloxicam and carprofen after dilution and suspension at two storage temperatures

Drug distribution and stability in extemporaneous preparations of meloxicam and carprofen after dilution and suspension at two storage temperatures

Stability of flucytosine 100 mg/mL suspension as an alternative to intravenous administration

Successful Treatment of Candida auris Ventriculitis With Intravenous Liposomal Amphotericin B and Oral Flucytosine: A Case Report

Contact Info

Product

Resources

About